Medtronic PLC $MDT Shares Acquired by Souders Financial Advisors

Souders Financial Advisors raised its stake in Medtronic PLC (NYSE:MDT) by 58.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,017 shares of the medical technology company’s stock after purchasing an additional 1,476 shares during the period. Souders Financial Advisors’ holdings in Medtronic were worth $350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in MDT. Brighton Jones LLC lifted its stake in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Penserra Capital Management LLC grew its position in shares of Medtronic by 164.7% in the 1st quarter. Penserra Capital Management LLC now owns 8,886 shares of the medical technology company’s stock valued at $797,000 after buying an additional 5,529 shares during the last quarter. U.S. Capital Wealth Advisors LLC raised its stake in Medtronic by 4.1% during the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 10,669 shares of the medical technology company’s stock worth $959,000 after acquiring an additional 421 shares in the last quarter. Stratos Wealth Advisors LLC lifted its position in Medtronic by 4.5% in the first quarter. Stratos Wealth Advisors LLC now owns 6,855 shares of the medical technology company’s stock valued at $616,000 after acquiring an additional 293 shares during the last quarter. Finally, Greenleaf Trust boosted its stake in Medtronic by 51.0% in the first quarter. Greenleaf Trust now owns 21,279 shares of the medical technology company’s stock valued at $1,912,000 after acquiring an additional 7,184 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on MDT shares. BTIG Research reissued a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a report on Sunday, November 2nd. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a report on Thursday, August 14th. Robert W. Baird lifted their price objective on shares of Medtronic from $94.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, August 20th. Finally, Sanford C. Bernstein reissued an “outperform” rating and set a $98.00 target price on shares of Medtronic in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $102.82.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director William R. Jellison acquired 2,500 shares of Medtronic stock in a transaction that occurred on Monday, August 25th. The shares were purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the purchase, the director directly owned 5,000 shares of the company’s stock, valued at $461,850. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.26% of the company’s stock.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $90.10 on Friday. The business has a 50-day moving average of $94.21 and a two-hundred day moving average of $89.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $99.37. The firm has a market capitalization of $115.57 billion, a PE ratio of 24.82, a P/E/G ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.